Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 4
1987 1
1992 1
1993 3
1994 3
1995 3
1996 1
1998 4
1999 1
2000 1
2001 4
2002 17
2003 27
2004 65
2005 82
2006 109
2007 115
2008 108
2009 141
2010 113
2011 127
2012 146
2013 147
2014 155
2015 141
2016 151
2017 118
2018 101
2019 104
2020 113
2021 130
2022 101
2023 134
2024 131
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,285 results

Results by year

Filters applied: . Clear all
Page 1
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J. Schweitzer PK, et al. Am J Respir Crit Care Med. 2023 Dec 15;208(12):1316-1327. doi: 10.1164/rccm.202306-1036OC. Am J Respir Crit Care Med. 2023. PMID: 37812772 Free PMC article. Clinical Trial.
Objectives: The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA. Methods: Phase II randomized, double-blind, plac …
Objectives: The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybut …
Atomoxetine in-focus!
Naguy A, Al-Enezi N, AlShalabi SR. Naguy A, et al. Asian J Psychiatr. 2020 Mar;49:101634. doi: 10.1016/j.ajp.2019.02.008. Epub 2019 Feb 13. Asian J Psychiatr. 2020. PMID: 30797701 No abstract available.
Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Fu D, Guo HL, Hu YH, Fang WR, Liu QQ, Xu J, Wu DD, Chen F. Fu D, et al. Eur J Clin Pharmacol. 2023 Mar;79(3):349-370. doi: 10.1007/s00228-022-03449-1. Epub 2023 Jan 16. Eur J Clin Pharmacol. 2023. PMID: 36645468 Review.
PURPOSE: There is marked heterogeneity in treatment response of atomoxetine in patients with attention deficit/hyperactivity disorder (ADHD), especially for the pediatric population. This review aims to evaluate current evidence to characterize the dose-exposure relationsh …
PURPOSE: There is marked heterogeneity in treatment response of atomoxetine in patients with attention deficit/hyperactivity disorder …
The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
Pringsheim T, Hirsch L, Gardner D, Gorman DA. Pringsheim T, et al. Can J Psychiatry. 2015 Feb;60(2):42-51. doi: 10.1177/070674371506000202. Can J Psychiatry. 2015. PMID: 25886655 Free PMC article. Review.
METHOD: We performed a systematic review and meta-analysis of psychostimulants, alpha-2 agonists, and atomoxetine for oppositional behaviour, conduct problems, and aggression in youth with ADHD, ODD, and CD. ...CONCLUSIONS: Evidence indicates that psychostimulants, alpha-2 …
METHOD: We performed a systematic review and meta-analysis of psychostimulants, alpha-2 agonists, and atomoxetine for oppositional be …
Atomoxetine-Associated Angular Cheilitis.
Kirlioglu SS, Unaldi N. Kirlioglu SS, et al. Am J Ther. 2022 Sep-Oct 01;29(5):e605-e606. doi: 10.1097/MJT.0000000000001168. Epub 2020 Mar 25. Am J Ther. 2022. PMID: 32235145 No abstract available.
The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A. Taranto-Montemurro L, et al. Am J Respir Crit Care Med. 2019 May 15;199(10):1267-1276. doi: 10.1164/rccm.201808-1493OC. Am J Respir Crit Care Med. 2019. PMID: 30395486 Free PMC article. Clinical Trial.
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in peo …
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimusc …
Current Pharmacological Treatments for ADHD.
Groom MJ, Cortese S. Groom MJ, et al. Curr Top Behav Neurosci. 2022;57:19-50. doi: 10.1007/7854_2022_330. Curr Top Behav Neurosci. 2022. PMID: 35507282 Review.
Currently approved pharmacological treatments for ADHD include a range of stimulant (methylphenidate, amphetamine) and nonstimulant (atomoxetine, guanfacine, clonidine) medications. All have been shown to be effective in treating the symptoms of ADHD and improving other fu …
Currently approved pharmacological treatments for ADHD include a range of stimulant (methylphenidate, amphetamine) and nonstimulant (atom …
Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S, Nebhinani N, Viswanathan A, Kirubakaran R. Patra S, et al. Autism Res. 2019 Apr;12(4):542-552. doi: 10.1002/aur.2059. Epub 2019 Jan 17. Autism Res. 2019. PMID: 30653855 Free article.
Atomoxetine is prescribed to children with autism spectrum disorder having symptoms of attention deficit hyperactivity disorder. ...However, atomoxetine was also associated with increased risk of non-serious adverse effects like nausea and vomiting, decreased sleep, …
Atomoxetine is prescribed to children with autism spectrum disorder having symptoms of attention deficit hyperactivity disorder. ...H …
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Mechler K, Banaschewski T, Hohmann S, Häge A. Mechler K, et al. Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23. Pharmacol Ther. 2022. PMID: 34174276 Free article. Review.
Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine). While available pharmacological treatment options for ADHD show relatively large effect sizes (in short-term trials) and overall good tolerabil …
Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine). Whi …
Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis.
di Giacomo E, Confalonieri V, Tofani F, Clerici M. di Giacomo E, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2443648. doi: 10.1001/jamanetworkopen.2024.43648. JAMA Netw Open. 2024. PMID: 39504019 Free PMC article.
OBJECTIVE: To examine adverse effects in offspring of mothers receiving treatment with atomoxetine and methylphenidate during pregnancy. DATA SOURCES: Electronic databases (PubMed, Embase, and PsycINFO) were searched for articles published through December 31, 2023, with t …
OBJECTIVE: To examine adverse effects in offspring of mothers receiving treatment with atomoxetine and methylphenidate during pregnan …
2,285 results

Searches related to "atomoxetine"